|
ENHANCING T CELL THERAPY OF CANCER
|
5P01CA094237-15
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-12
|
$249,637
|
$249,637
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
$4,733
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
$4,755
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
$4,890
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
$10,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
$130,125
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-04
|
$326,348
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of m6A mRNA methylation in Neuroblastoma
|
1R21CA219352-01
|
$246,472
|
$246,472
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$111,482
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-04
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$1,803,769
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Structural Variation in Neuroblastoma
|
5R01CA204974-02
|
$384,300
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Altered mitochondria-ER signaling as a cause of chemotherapy resistance
|
5R21CA198430-02
|
$215,064
|
$215,064
|
HOGARTY, MICHAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes
|
1R35CA220500-01
|
$683,163
|
$683,163
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-10
|
$614,290
|
$614,290
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
5R01CA180692-03
|
$606,838
|
$606,838
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Pediatric Preclinical Testing Consortium
|
5U01CA199287-03
|
$357,000
|
$357,000
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-09
|
$374,324
|
$374,324
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exosomes in tumor cell-mesenchymal stromal cell interaction
|
1R01CA207983-01A1
|
$423,016
|
$296,111
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-10
|
$239,246
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-22
|
$136,153
|
$68,077
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Role of microRNAs released by Tumor Associated Macrophages within Exosomes in the chemoresistance of Neuroblastoma
|
1R01CA215753-01A1
|
$391,698
|
$391,698
|
FABBRI, MULLER
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
|
1P01CA217959-01
|
$2,296,936
|
$2,296,936
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Bench to bedside: non-invasive treatment of tumors in children
|
1U01CA202947-01A1
|
$350,585
|
$87,646
|
KIM, PETER
|
CHILDREN'S RESEARCH INSTITUTE
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-03
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S2
|
$60,000
|
$600
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S3
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
5R01CA172067-06
|
$363,425
|
$363,425
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
2R01CA148688-06A1
|
$413,844
|
$413,844
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
5R01CA197336-02
|
$407,748
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
2P30CA006516-52
|
$11,592,798
|
$115,928
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S1
|
$112,500
|
$1,125
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
The Role of LIN28B Signaling in Mediating the Oncogenic Phenotype in Neuroblas
|
5K08CA194162-03
|
$168,264
|
$168,264
|
SCHNEPP, ROBERT
|
EMORY UNIVERSITY
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
5R01CA123490-10
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-26
|
$635,460
|
$317,730
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Neuropeptide Y (NPY) as a hypoxia-driven metastatic factor
|
5R01CA197964-03
|
$348,597
|
$174,299
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
3P30CA051008-24S1
|
$166,654
|
$1,667
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
5P30CA051008-24
|
$2,258,441
|
$22,584
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
Targeting nutrient-sensing pathways in cancer
|
5K22CA201103-02
|
$191,360
|
$191,360
|
LAZARUS, MICHAEL
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma
|
5R00CA178189-05
|
$249,000
|
$249,000
|
ZHU, SHIZHEN
|
MAYO CLINIC ROCHESTER
|
|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$104,000
|
N/A
|
National Institutes of Health
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,583,320
|
$179,166
|
Glod, John
|
CCR (NCI)
|
|
Development of new antibody-based cancer therapies
|
ZIA BC 010891
|
$942,291
|
$942,291
|
Ho, Mitchell
|
CCR (NCI)
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
$47,481
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Biomarkers and Therapeutic Targets in Angiogenesis and Metastasis
|
ZIA BC 011334
|
$474,811
|
$47,481
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Developing Novel Therapies for Neuroblastoma and Rhabdomyosarcoma
|
ZIA BC 010806
|
$170,385
|
$85,192
|
Khan, Javed
|
CCR (NCI)
|
|
Identification of Novel Mutations In Pediatric Cancers
|
ZIA BC 010998
|
$511,155
|
$204,462
|
Khan, Javed
|
CCR (NCI)
|
|
Bioinformatics: Systems Biology of Pediatric Cancers
|
ZIA BC 011002
|
$340,770
|
$340,770
|
Khan, Javed
|
CCR (NCI)
|
|
Identification of Genes for Predicting Prognosis in Pediatric Cancers
|
ZIA SC 010366
|
$170,385
|
$85,192
|
Khan, Javed
|
CCR (NCI)
|
Total relevant funding to Neuroblastoma for this search: $23,594,430
|